is now approved

as the first and only once-weekly treatment indicated to increase linear growth in children 2 years of age and older with achondroplasia whose growth plates are open.

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
PAL icon

One-on-one support is available

Your dedicated Patient Access Liaison (PAL) can help provide individualized support and education.

Connect with a PAL
Bell icon

A•S•A•P can help throughout treatment

From starting therapy to navigating insurance, the Ascendis Signature Access Program (A•S•A•P) can help you stay on track.

Explore support

Connect with a PAL and register for updates

A Patient Access Liaison (PAL) can provide you with individualized support and education about achondroplasia and treatment with YUVIWEL. Fill out the form below to receive important information about YUVIWEL and connect with a PAL.

*Required field.

Connect With a PAL

By checking this box, I confirm that I would like an Ascendis Patient Access Liaison to contact me with information about achondroplasia and YUVIWEL. I understand the PAL is not providing me medical advice and is not part of my healthcare team. I understand that Ascendis will use reasonable measures to protect the information I share with the PAL and will not use or disclose it outside of the company.

A PAL will reach out to you via phone.

Privacy Notice

By checking this box, I certify that I am a resident of the United States and 18 years or older and agree to Ascendis Pharma Terms of Use. I understand and agree that the information I provide will be used in line with the Ascendis Pharma Privacy Policy, including to provide me with marketing information, such as newsletters and updates, and to contact me for my opinion regarding products, programs, and services.

I understand that at any time I may unsubscribe by clicking on the designated link in the material.

Consent

By checking this box, I confirm that I have given my consent to the collection and processing of the information provided as answers marked with *. This information will solely be used to tailor our communications to you. You may at any time withdraw your consent. For more information, please see our Privacy Policy.

USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?

  • YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).
  • YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?

  • YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).
  • YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?

YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child’s healthcare provider.

The most common side effects of YUVIWEL include injection site reactions (redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering).

Before you give YUVIWEL to your child, tell the healthcare provider about all of your child’s medical conditions, including if they:

  • have kidney problems
  • are pregnant or plan to become pregnant. It is not known if YUVIWEL will harm the unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if YUVIWEL passes into breast milk

Tell the healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of YUVIWEL. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please see full Prescribing Information and Patient Information for YUVIWEL.

FDA=US Food and Drug Administration.